Mitomycin Accord (Mitomycin)

Mitomycin is a bioreductive alkylating agent. Inside low‑oxygen tumour cells it is reduced to a highly reactive form that cross‑links DNA strands, blocking DNA synthesis and triggering programmed cell death. This mechanism preferentially affects rapidly dividing cancer cells.

The dose of Mitomycin Accord is determined individually by the treating physician based on the specific cancer type, stage, patient weight, renal function and other clinical factors. Only a qualified prescriber can set the appropriate dosing schedule.

Mitomycin is classified as contraindicated in pregnancy and breastfeeding because of its potential to cause fetal harm and to be excreted in breast milk. It should only be used if the potential benefits outweigh the risks and under strict medical supervision.

To request Mitomycin Accord, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with other alkylating agents, mitomycin has a unique bioreductive activation that targets hypoxic tumour cells, offering a distinct mechanism of action. It is often chosen for tumours where other agents have limited efficacy, but the overall choice depends on the cancer type, patient condition and treatment protocol.

Mitomycin Accord must be stored at 2‑8 °C in a refrigerator, protected from light. The vial should remain in its original packaging, should not be frozen, and must be handled gently to avoid shaking, which could affect stability.

Mitomycin Accord is supplied as an injectable solution. It can be given intravenously as an infusion or instilled intravesically directly into the bladder, depending on the indication. Administration is performed by qualified healthcare professionals in a clinical setting.

The most serious risks include severe bone‑marrow suppression leading to infections, pulmonary fibrosis, hemolytic‑uremic syndrome, and rare but life‑threatening allergic reactions. Patients should be monitored closely for signs of these complications throughout treatment.

Mitomycin Accord should not be used in patients with known hypersensitivity to mitomycin, severe renal impairment, active uncontrolled infections, or in pregnant or breastfeeding women unless absolutely necessary. Clinicians must evaluate each patient’s medical history before prescribing.